David A. Siegel Tango Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $43.8 Billion
- Q2 2024
Shares
2 transactions
Others Institutions Holding TNGX
# of Institutions
119Shares Held
89.1MCall Options Held
2.6KPut Options Held
1K-
Trv Gp Iv, LLC Boston, MA19.2MShares$148 Million81.48% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA13.3MShares$103 Million4.04% of portfolio
-
Boxer Capital, LLC San Diego, CA8.2MShares$63.1 Million3.91% of portfolio
-
Nextech Invest Ag5.53MShares$42.6 Million8.96% of portfolio
-
Southpoint Capital Advisors LP New York, NY5.28MShares$40.6 Million1.32% of portfolio
About Tango Therapeutics, Inc.
- Ticker TNGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 88,067,296
- Market Cap $678M
- Description
- Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops...